Collagen Induced Arthritis (CIA) in Rat
Rat collagen induced arthritis (CIA) is an experimental model of polyarthritis that has been widely used for preclinical testing of numerous anti-arthritic agents, which are either under preclinical or clinical investigation, or are currently used as therapeutics in this disease..
On study day 0 and day 7, female rats are given intradermal injections of bovine or porcine type II collagen (1 to 2 mg/mL in incomplete Freund’s Adjuvant) at multiple sites on the lower back.
The resulting polyarthritis (occurring on or around day 11) is characterized by marked cartilage destruction associated with immune complex deposition on articular surfaces, bone resorption and periosteal proliferation, and moderate to marked synovitis and periarticular inflammation1,2,3. The lesions in type II collagen arthritis are somewhat more analogous to those seen in human RA than are the lesions of adjuvant arthritis in that there is more extensive pannus associated cartilage destruction. However, adjuvant arthritis has been used much more extensively for pharmaceutical testing and therefore more data exists for comparison in humans.
- Developing (Prophylactic) – Begin dosing on study day 0 (or earlier) and continue until necropsy on day 17 (out to day 34).
- Semi-Established (Prophylactic) – Begin dosing on study day 6 or 9 and continue until necropsy on day 17 (out to day 34).
- Established (Therapeutic) – Begin dosing on study day 11 to 13 and continue until necropsy on day 17 (out to day 34).
- Route of administration: SC, PO, IP, IV
Caliper measurements of ankle joint width are done on study days 9 through termination. At termination, the tibiotarsal joint is transected at the level of the medial and lateral malleolus for determination of paw weights as another measure of inflammation.
Fore paws, hind paws/ankles, and knees are given scores of 0 through 5 for inflammation, pannus formation, cartilage damage and bone resorption according to these methods.
Sample Data (Click on Image to Enlarge):
Representative Photomicrographs of Ankle/Knee Joints (Normal, 17-Day Arthritis and 34-Day Arthritis)
For additional examples of positive controls, please contact us.
Clinically used agents that show activity in established collagen arthritis include corticosteroids, indomethacin and to a lesser extent, methotrexate4. Biological agents such as IL-1ra and the soluble TNF receptors are active in this test system and combination therapies with IL-1 ra and PEG sTNF-RI show potential for greater than additive effects5. Activity of commonly used small molecule anti-arthritic agents such as dexamethasone, indomethacin (and other NSAIDs including cyclo-oxygenase 2 inhibitors) and methotrexate eare predicted by the established rat type II collagen arthritis models.
- PK/PD blood collections
- Cytokine/chemokine analysis via Luminex(R)
- Other sandwich ELISAs
- CBC/clinical chemistry analysis
- Soft tissue collection
- Histopathologic analysis
- Immunohistochemistry analysis
- Bendele AM. Animal Models of Rheumatoid Arthritis. J Musculoskel Interact 2001; 4: 377– 385
- Bendele A, Chlipala L, Sennello R, Frazier J, Edwards C. Combination benefit of treatment with soluble TNF- RI and IL-1ra in rat models of arthritis. Arthritis Rheum 2000; 43:2648-2659.
- Bendele AM, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, Guy M. Animal models of arthritis: relevance to human disease. Toxicologic Pathol 1999; 27:134-142.
- Terato K, Hashida R, Miyamoto K, Morimoto T, Kata, Y, Kobayashi S, Tajima T, Otake S, Horni ∏, Nagai Y. Histological, immunological and biochemical studies on type II collagen arthritis in rats. Biomed Res 1982; 3:495-523
- Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146(3): 857–868